Hub · Peptides in Perth: Research, Delivery and WA Law
CJC-1295 in Perth
CJC-1295 in Perth needs a form-specific reading: Form Laboratories lists No DAC material with ipamorelin in one research-only blend, while DAC papers describe a different form; the catalogue gives no component split. The October 2026 Poisons Standard, checked on 1 October 2026, lists CJC-1295 with a CAS qualifier and ipamorelin separately in Schedule 4 and Appendix D, without deciding the status of this blend.
Deep into the night, while you sleep, your body releases growth hormone in bursts. The catalogue's receptor explanation places that rhythm behind two different research tracks. A search for CJC-1295 in Perth, though, can leave three names tangled together: a DAC form, a No DAC form and ipamorelin. Untangling the names is this page's role in the Perth research peptides hub.
The useful first step is separation. A chemical tag belongs to one form, a separate identity paper belongs to another molecule, and a catalogue listing has its own contents description. The records become easier to read when each keeps its label. Here the literature supplies background for names and methods, while the legal text and dispatch record answer different questions.
Key facts
| Compound A | CJC-1295 (No DAC) / Modified GRF (1-29) — catalogue |
|---|---|
| No DAC formula | C152H252N44O42 — catalogue |
| No DAC molecular weight | 3367.9 g/mol — catalogue |
| No DAC CAS | Not recorded in the catalogue |
| Compound B | Ipamorelin / NNC 26-0161 — catalogue |
| Ipamorelin CAS | 170851-70-4 — catalogue |
| Ipamorelin formula | C38H49N9O5 — catalogue |
| Ipamorelin molecular weight | 711.9 g/mol — catalogue |
| Product format | One vial, two-compound blend; component split unstated — catalogue |
| DAC literature | Jette et al., Endocrinology, 2005 |
| Ipamorelin identity paper | Raun et al., European Journal of Endocrinology, 1998 |
| Named schedule entries | Schedule 4 and Appendix D clause 5; F2026L01327; checked 1 October 2026 UTC |
| CJC-1295 legal qualifier | CAS 863288-34-0 in the instrument; no DAC form specified |
| Storage | 2–8 C — catalogue |
What does the CJC-1295 name identify?
CJC-1295 is used for forms with and without a Drug Affinity Complex, or DAC, in the catalogue and its literature record. The DAC is an added chemical group studied with albumin, a blood protein. The No DAC catalogue entry is also called Modified GRF (1-29). Ipamorelin is a separate molecule. Sharing a listing does not make those identities the same.
The CJC-1295 and ipamorelin research guide keeps the forms separate. The catalogue records C152H252N44O42 and 3367.9 g/mol for the No DAC description. A formula counts the atoms in a molecular description; molecular weight records its mass on a chemical scale. Neither field specifies the proportion of that compound in a blend. Detection papers and DAC literature examine different parts of the naming problem. That distinction survives here: methods used to identify material answer a different question from papers that examine biological responses.
Evidence limits
What can the CJC-1295 records on this page not establish?
The CJC-1295 records here do not establish a combined effect for the catalogue blend, a component split, or the identity of its listed lot. DAC research remains labelled as DAC research. No DAC detection papers remain analytical evidence about their stated samples. The TGA's 13 April 2026 advisory includes CJC-1295 among unapproved peptide examples. A literature list cannot substitute for product evaluation or sample testing.
Henninge and colleagues' 2010 Drug Testing and Analysis paper and Memdouh and colleagues' 2021 paper in the same journal form the analytical source set here. They address detection and characterisation. Jette's DAC paper addresses a different form, while Raun's paper concerns ipamorelin. The names and methods stay beside those sources. This page makes no exhaustive claim that a particular kind of study has never existed. It describes laboratory research material only and gives no directions for human or animal application. No clinical outcome is attributed to the supplied material.
What does No DAC mean on CJC-1295?
No DAC means the Drug Affinity Complex is absent from the CJC-1295 description. Jette and colleagues' Endocrinology paper in 2005 describes a tagged form with an added chemical group at one end of the molecule. That paper supplies the background for the naming split. The Form Laboratories catalogue lists the untagged No DAC form. The two labels must stay attached to their own materials.
A hook is a simple picture for the added group. The useful part of that picture is structural: an added group changes the molecule described. Jette's team studied tagged derivatives and their association with albumin in laboratory and rat systems. That experimental label cannot be removed when the paper is cited elsewhere. A paper about the tagged material is not direct evidence for an untagged sample. The distinction here concerns chemical names and source attribution. It does not compare the forms as choices for an intended application.
Is CJC-1295 the same molecule as ipamorelin?
CJC-1295 and ipamorelin are separate molecules in the Form Laboratories catalogue. Ipamorelin has its own formula, C38H49N9O5, molecular weight of 711.9 g/mol and recorded CAS identifier, 170851-70-4. Raun and colleagues' 1998 European Journal of Endocrinology paper is the cited ipamorelin identity source. A single catalogue blend can contain different compounds without turning them into one molecular identity.
The catalogue's research code for ipamorelin is NNC 26-0161. Its No DAC CJC-1295 field has no recorded CAS number. CAS is an identifier system for chemical substances, rather than a test result. The asymmetry is useful: one molecule has a recorded catalogue identifier and the other has a gap. Filling that gap with a number from a different form would obscure the very distinction the page explains. The table below places the recorded identity fields side by side. It contains no outcome column and no suggested application for either molecule.
How should the receptor literature be read beside CJC-1295?
CJC-1295 and ipamorelin occupy different research tracks in the catalogue: GHRH analogue research and ghrelin-receptor research. GHRH means growth-hormone-releasing hormone; an analogue is a related molecule. A receptor is a protein that receives a molecular signal. Howard and colleagues' Science paper in 1996 supplies receptor background. That background does not establish a finding for a blend containing both catalogue compounds.
Howard's receptor work sits beside Raun's ipamorelin identity work. Keeping them separate is more useful than treating a shared research topic as a shared result. A receptor paper can describe the molecular target studied without being a test of the product listed here. The same care applies when comparing another GHRH analogue in the tesamorelin research guide: a common class name leaves the individual molecular description and study methods intact. No combined outcome is inferred from catalogue proximity or from related vocabulary in the literature.
What is the Australian schedule status of CJC-1295 and ipamorelin?
The October 2026 Poisons Standard, F2026L01327, checked on 1 October 2026 UTC, lists CJC-1295 with CAS 863288-34-0 and ipamorelin separately in Schedule 4. Both also appear in Appendix D clause 5, at items 7 and 25 respectively. The CJC-1295 entry specifies no DAC form. Those entries record classifications; this page does not decide their application to a particular formulation or blend.
The June instrument checked in the September research record already contained those named entries. The live Australian-law guide records the superseding October edition. The important CJC-1295 caveat survives the update: the instrument's CAS qualifier is not a missing catalogue identifier that can simply be copied into the No DAC field. The source text and catalogue answer different questions. Appendix D clause 5 records a control on possession without authority. How scheduling reaches Western Australia explains the state-law route. A research-use label creates no legal permission of its own.
CJC-1295 is also named in the TGA's advisory of 13 April 2026. Ipamorelin does not appear in that advisory's example list, while the June advertising guidance names it. The example list is not an exhaustive classification table. Reading the two notices for their own purposes prevents an absence from one list being treated as clearance. This page states no ARTG lookup result for either catalogue compound and gives no verdict about an individual's authority to possess or supply a product.
Why does TGA advertising guidance name CJC-1295 and ipamorelin?
The TGA advertising guidance published on 18 June 2026 names CJC 1295 and Ipamorelin as examples of prescription-medicine references restricted in public advertising. The same guidance includes BPC 157 and the class word Peptides. Naming a class instead of an individual substance does not settle the advertising question. The guidance concerns public references to medicines, separate from the catalogue's molecular descriptions.
Exact naming makes the regulatory distinction clearer. CJC-1295 appears in the April advisory's unapproved-product examples. Ipamorelin appears in the June advertising guidance. Neither statement should be silently converted into the other. The TGA's April notice also says that a research-use disclaimer does not change regulatory status, permit importation or remove advertising and supply duties. Factual education therefore needs its own careful wording. Scientific terms, dated legal entries and an explanation of evidence limits are the subjects here; a promised result from the material is not part of that explanation.
Are CJC-1295 and ipamorelin named in the sport record?
Sport Integrity Australia's peptide record, retrieved on 9 September 2026, names CJC-1295 and ipamorelin among peptides prohibited in sport. The CJC-1295 name in that record does not specify a DAC form. The sporting source answers a sport question. It does not resolve the catalogue's missing identifier or the legal interpretation of a blend. The source name and date therefore remain part of the statement.
The naming problem does not end when the document changes. A catalogue distinguishes No DAC material; a paper describes its study sample; a sport source uses its own listed names. Reading the labels as written is more precise than assuming that every occurrence of CJC-1295 refers to identical material. The sporting source cited here is Sport Integrity Australia. It is not presented as a verbatim extract from another body's prohibited list. The appropriate official record must be checked for its own rules and any later update.
What is recorded for the CJC-1295 blend and Perth dispatch?
The CJC-1295 and ipamorelin catalogue listing describes one vial containing a blend, with the component split unstated. Its recorded storage condition is 2–8 C. Form Laboratories' shipping record says payment must clear and be matched before Perth dispatch. Certificates of Analysis are available on request. The molecular fields describe the components, while an available report must be checked for the sample and lot it actually covers.
The CJC-1295 and ipamorelin reference-material listing is one product record. It does not describe two separate vials. Neither the combined label nor the individual molecular weights supplies a component ratio. The explanation of what a lot number lets a researcher check gives the paperwork context. A report on another sample cannot close a missing current-lot check. The page makes no claim that every product has a matched current report and no identity or purity guarantee.
The shipping page for Form Laboratories in Perth records Australia Post or CouriersPlease carriage within Australia and a tracking email after handover. The outer parcel is plain. Those details describe dispatch rather than the chemistry of the blend. The national shipping windows are not a separately guaranteed Perth arrival time, and this article states no temperature assurance for transit. One parcel, one product listing and two component descriptions are different records. Keeping them separate is the practical end of the naming exercise that began with DAC and No DAC.
Comparison
Two molecular descriptions within one catalogue blend: identity sources, formulae, weights, identifiers and regulatory naming.
| Criterion | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|
| Literature context | Jette 2005 concerns DAC background; Henninge 2010 concerns analytical identification | Raun 1998 is the ipamorelin identity source |
| Formula | C152H252N44O42 — catalogue | C38H49N9O5 — catalogue |
| Molecular weight | 3367.9 g/mol — catalogue | 711.9 g/mol — catalogue |
| Catalogue CAS | Not recorded; instrument qualifier is not assigned to this catalogue form | 170851-70-4 |
| April 2026 TGA examples | CJC-1295 named; no form specified | Not in the advisory's example list |
| June 2026 advertising guidance | CJC 1295 named | Ipamorelin named |
FAQ
Does No DAC identify the same material as Jette's CJC-1295 paper?
No DAC describes the absence of the added chemical group. Jette's 2005 Endocrinology paper concerns the tagged DAC form. That paper remains background for the naming distinction, rather than direct evidence about the No DAC catalogue material.
Does the CJC-1295 legal CAS fill the No DAC catalogue gap?
The October 2026 instrument, checked on 1 October 2026, names CJC-1295 with CAS 863288-34-0 but no DAC form. The catalogue supplies no No DAC CAS. This page preserves both records and does not assign the instrument's number to the catalogue material.
Are CJC-1295 and ipamorelin supplied as two separate vials?
The Form Laboratories listing describes one vial containing a two-compound blend. The component split is unstated. Individual formulae and molecular weights describe the two molecular identities; they do not establish their proportion in that vial.
Why is ipamorelin absent from the April examples but named in June?
The TGA's April 2026 advisory and June 2026 advertising guidance answer different questions. CJC-1295 is in the advisory's example list; ipamorelin is named in the advertising guidance. An example list is not exhaustive and its omissions do not grant regulatory permission.
Part of
Peptides in Perth: Research, Delivery and WA LawForm Laboratories is a Perth-based supplier of research-use-only peptides that dispatches Australia-wide after payment clears, as its shipping page states. Australian and Western Australian law still apply to each substance; a research-use-only label does not make supply lawful (TGA advisory, 13 April 2026).
Citations
6 sourcesJette L et al. Endocrinology. 2005;146(7):3052–3058 — DAC form.
doi:10.1210/en.2004-1286Raun K et al. European Journal of Endocrinology. 1998;139(5):552–561.
doi:10.1530/eje.0.1390552Howard AD et al. Science. 1996;273(5277):974–977.
doi:10.1126/science.273.5277.974Henninge J et al. Drug Testing and Analysis. 2010;2(11–12):647–650.
doi:10.1002/dta.233Knoop A et al. Analytical and Bioanalytical Chemistry. 2016;408(12):3145–3153.
doi:10.1007/s00216-016-9377-3Memdouh S et al. Drug Testing and Analysis. 2021;13(11–12):1871–1887.
doi:10.1002/dta.3183
Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.